top of page

Slavich Noya Technology announces H1 2022 results

Slavich Noya Technology, part of the Rafarma Pharmaceuticals (OTC: RAFA) group of companies, shared its achievements, sales and production figures for the first half of 2022. Last year, the enterprise management team was replaced, which gave excellent results, reflected in financial performance. Slacivh is a notable industry player engaged in components, packaging and intermediates production for pharmacology and the development of logistics devices, colloidal chemistry products and photochemical products.

In the first half of this year, the company increased the nuclear film pouring volume and doubled the nuclear emulsion synthesis volume used in scientific research and exploration. In terms of consumer demand, it remains at a good level. For the specified period, Slavich Noya Technology attracted more than 90 new customers, retaining most of the current ones.

Photo paper sales show stolid growth: +86% from H1 2021 to H1 2022. The export sales indicator for the same period amounted to +145%. Revenue, in turn, increased by 98%, and only new clients brought the company more than $800,000.

Sales of photographic plates (including holographic) and photochemistry for photographic plates increased by 114% and revenue by 86% from the same period last year. Mikron's production, which is engaged in this area, shows a stable growth of +80% cumulative total (YTD June 2022) compared to the same period in 2021. Sales of printing products are in line with the company's expectations. Growth since 2021 was 28%.

Today the company is working on a new project - holographic sets. The company's team will conduct experiments to obtain a hologram, make a selection, and test LED lights. In addition, Slavich Noya Technology plans to purchase new machines for paper cups and plates production. These will significantly expand Slavich's operational capabilities.


Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.

For more information, please visit


Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.



(307) 429-2029

Source: Rafarma Pharmaceuticals, Inc.


bottom of page